The Progressive


A project of Common Dreams

For Immediate Release
Contact: Phone: (202) 588-1000

Handouts to Manufacturers Will Not Curb Opioid Abuse Epidemic


A provision tucked into a U.S. House of Representatives bill to address opioid addiction is nothing but an expensive handout to the pharmaceutical industry that will do little to address the epidemic, Public Citizen said in a letter to Congress.

Lawmakers in the conference committee for the Comprehensive Addiction and Recovery Act are scheduled to meet on Wednesday, July 6, for the first time to discuss the bill.

The provision - Section 803 - would give manufacturers of so-called "abuse-deterrent" forms of opioids unnecessary financial incentives under the Medicaid program for their products.

"There is absolutely no need to provide additional incentives to manufacturers to develop new abuse-deterrent pain products. Manufacturers already are heavily promoting abuse-deterrent formulations as the future of opioid pain relief," said Dr. Michael Carome, director of Public Citizen's Health Research Group. "Moreover, new abuse-deterrent products do not warrant expensive incentives because they have not yet been proven to substantially reduce the opioid abuse epidemic. If lawmakers are serious about fighting this public health crisis, they will oppose section 803."

Read the letter.

Public Citizen is a nonprofit consumer advocacy organization that champions the public interest in the halls of power. We defend democracy, resist corporate power and work to ensure that government works for the people - not for big corporations. Founded in 1971, we now have 500,000 members and supporters throughout the country.

(202) 588-1000